Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has signed an exclusive global licensing agreement with an AbbVie-controlled entity for RC148, its novel PD-1/VEGF-targeting bispecific antibody, granting AbbVie rights to develop, manufacture and commercialize the drug outside Greater China. The deal, effective upon regulatory clearance, provides RemeGen with a US$650 million upfront payment and potential milestone payments of up to US$4.95 billion plus tiered double‑digit royalties on ex‑Greater China sales, substantially strengthening its financial position and validating its oncology pipeline while positioning AbbVie to broaden its cancer portfolio with an innovative immuno-oncology asset.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$73.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China that develops innovative antibody-based therapies, including novel bispecific antibody drugs, with a focus on treating various advanced malignant solid tumors. The company holds proprietary intellectual property for its pipeline candidates and is actively advancing oncology products within China while seeking global partnerships to expand their reach beyond the Greater China region.
Average Trading Volume: 5,133,863
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$57.7B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.